

Special Issue

Recent Advances in Peritoneal Carcinomatosis

Message from the Guest Editors

Peritoneal carcinomatosis (PC) represents a complex and aggressive clinical challenge, characterized by its intricate tumor microenvironment (TME), poor prognosis, and limited therapeutic options. While cytoreductive surgery and intraperitoneal (IP) chemotherapy remain mainstays of treatment, they often fall short of delivering durable responses. This Special Issue seeks to spotlight the latest advancements in understanding and targeting PC, with a focus on next-generation treatment modalities that transcend conventional approaches. Emerging research highlights the pivotal role of the TME, immune cell infiltration, and the peritoneal microbiome in driving disease progression and therapeutic resistance. Additionally, the burgeoning field of microbiome–host interactions has revealed the profound influence of the peritoneal microbiome on tumor behavior, immune modulation, and therapy responsiveness.

This Special Issue welcomes original research articles, reviews, and communications from multidisciplinary teams, providing a platform to share innovative findings and foster collaborative opportunities.

Guest Editors

Dr. Neda Dadgar

Allegheny Health Network Cancer Institute, Pittsburgh, PA 15224, USA

Dr. Patrick L. Wagner

Allegheny Health Network Cancer Institute, Wexford, PA, USA

Deadline for manuscript submissions

31 December 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/225347

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)